Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation plan activity.
- Share Price: 1,571 pence per Ordinary Share; $50.84 per American Depositary Share (ADS).
- Transaction Type: Notional increases in share interests following the re-investment of dividends paid on October 3, 2013.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document details specific increases in notional share holdings for various executives, including Sir Andrew Witty (17,855.571 Ordinary Shares) and Dr. M M Slaoui (5,353.520 ADSs), among others.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It notes that notional dividends accrued will be paid out proportionally based on the percentage of Performance Share Plan holdings that vest after the relevant measurement period.
Investor Verification Points
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares outstanding and the impact of these notional increases on executive ownership percentages.
- Review the dividend payment date (October 3, 2013) to ensure alignment with the company's broader dividend policy.